Skip to main content
Equibles
TEVA logo

TEVA · Teva Pharmaceutical Industries Ltd · Metrics

Track TEVA — free

Use TEVA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TEVA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$39.41 -0.80 (-1.99%) At close · Oct 23
Rebalance outlook locked
Market Cap
$45.92B
Shares
1.17B
Volume · Oct 23 5.6M Avg daily vol (3M) 5.69M

TEVA metrics

95 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$39.41
Market cap
$45.92B

Price action

20 metrics
Price change (1W)
-5.0%
Price change (30D)
+0.6%
Price change (3M)
+27.9%
Price change (6M)
+28.6%
Price change (YTD)
+26.3%
Price change (1Y)
+107.2%
Trailing year
Price change (5Y)
+289.0%
52-week high
$41.50
52-week low
$18.95
Change from 52-week high
-5.0%
Change from 52-week low
+108.0%
Annualized volatility
39.2%
Annualized volatility (3M)
32.3%
Beta
0.7
RSI (14D)
46.9
Price vs SMA 50
+1.9%
Price vs SMA 200
+14.7%
Avg volume (3M)
5.69M
Relative volume
1.0
Average dollar volume
$215.40M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
1.17B

Valuation

12 metrics
P / E (TTM)
64.6
Trailing earnings · reciprocal yield 1.5%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
3.3×
reciprocal yield 30.7%
P / book
5.9
reciprocal yield 16.9%
FCF yield
2.9%
TTM · current market cap
Buyback yield
0.0%
P / FCF
34.1
reciprocal yield 2.9%
P / operating cash flow
24.2
reciprocal yield 4.1%
Earnings yield
1.5%

Historical valuation

8 metrics
P / E historical average (3Y)
38.6×
reciprocal yield 2.6%
P / E historical average (5Y)
31.9×
reciprocal yield 3.1%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-03
Last earnings
2026-09-02

Profitability

9 metrics
Gross margin
64.4%
Operating margin
11.4%
Trailing 12 months
Net margin
5.0%
Gross profit (TTM)
$9.08B
Operating profit (TTM)
$1.60B
Net income (TTM)
$707.00M
Trailing 12 months
Diluted EPS (TTM)
$0.61
FCF margin
9.6%
Effective tax rate
1.7%

Per share

11 metrics
Revenue per diluted share (TTM)
$12.07
Gross profit per diluted share (TTM)
$7.77
Operating profit per diluted share (TTM)
$1.37
EBITDA per diluted share (TTM)
$2.21
Net income per diluted share (TTM)
$0.60
Operating cash flow per diluted share (TTM)
$1.63
Free cash flow per diluted share (TTM)
$1.16
Capital expenditures per diluted share (TTM)
$0.47
R&D per diluted share (TTM)
$1.47
Stock compensation per diluted share (TTM)
$0.14
Book value per share
$6.65

Growth

11 metrics
Revenue growth YoY
-0.8%
Year over year
Net income growth YoY
-304.3%
Revenue (TTM)
$14.10B
Trailing 12 months
EPS growth YoY
-304.2%
Shares change YoY
+0.3%
Year over year · more shares
Revenue CAGR (3Y)
+5.0%
Revenue CAGR (5Y)
+0.7%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
+3.3%
FCF CAGR (5Y)
+12.5%

Quality

14 metrics
Return on equity
9.1%
Return on assets
1.8%
Debt / equity
—
Current ratio
0.9
EBITDA (TTM)
$2.59B
Free cash flow (TTM)
$1.35B
Quick ratio
0.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$3.65B
Total assets
$39.86B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$1.90B
Capital expenditures (TTM)
$550.00M
R&D (TTM)
$1.71B
SG&A (TTM)
—
Stock compensation (TTM)
$168.00M
R&D / revenue
12.2%
Stock compensation / revenue
1.2%

Ownership (13F)

9 metrics
13F filers
683
13F filer change QoQ
+22
Institutional ownership
65.4%
Conviction holders (share of 13F filers)
3.7%
Crowding (high-turnover and private-fund holders)
11.2%
Private-fund adviser ownership
10.8%
Active holders' share change QoQ
+4.0%
Holder tenure
18.2
Price vs estimated holder cost
+46.3%

Ownership (registered funds)

1 metrics
Index-fund ownership
4.5%

Short interest

3 metrics
Short interest
2.6%
Latest settlement · 5.4 days to cover
Days to cover
5.4d
Short-squeeze score
56 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$17.03M
Insider-sentiment score
13 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 818686 CUSIP M8769Q102 13F (30d) 114 filings 102 filers Visit website Investor relations